At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
VOR Vor Biopharma Inc.
Closed Independence Day 07-02 16:00:00 EDT
20.59
+2.20
+11.96%
盘后20.56
-0.03-0.15%
19:49 EDT
High22.22Low18.67Vol3.91M
Open18.72D1 Closing18.39Amplitude19.29%
Mkt Cap1.12BTradable Cap900.00MTotal Shares54.19M
T/O81.64MT/O Rate8.95%Tradable Shares43.71M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Vor Bio Grants Inducement Awards to New Hires, Including Options for 71,200 Shares at $18.39
Reuters  ·  05:30
Vor Bio Grants Inducement Awards to New Hires, Including Options for 71,200 Shares at $18.39
Vor Bio Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
THOMSON REUTERS  ·  05:30
Vor Bio Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Vor Biopharma shareholders back directors and governance measures
TIPRANKS  ·  06-13
Vor Biopharma shareholders back directors and governance measures
Vor Biopharma shareholders approved amended 2021 equity incentive plan at annual meeting
Reuters  ·  06-13
Vor Biopharma shareholders approved amended 2021 equity incentive plan at annual meeting
Vor Bio gains boost from telitacicept IgA nephropathy approval
TIPRANKS  ·  06-09
Vor Bio gains boost from telitacicept IgA nephropathy approval
Vor Bio Partner Drug Earns Regulatory Approval In China For Sjogren's Disease
MT Newswires Live  ·  06-08
Vor Bio Partner Drug Earns Regulatory Approval In China For Sjogren's Disease
Vor Bio says China NMPA approves telitacicept for Sjögren’s disease
Reuters  ·  06-08
Vor Bio says China NMPA approves telitacicept for Sjögren’s disease
Vor Bio says telitacicept wins China conditional approval for IgA nephropathy
Reuters  ·  06-08
Vor Bio says telitacicept wins China conditional approval for IgA nephropathy
Telitacicept Receives Nmpa Conditional Approval for the Treatment of Iga Nephropathy in China
THOMSON REUTERS  ·  06-08
Telitacicept Receives Nmpa Conditional Approval for the Treatment of Iga Nephropathy in China
Vor Biopharma’s Phase 3 Sjögren’s Trial Puts Telitacicept on Investors’ Radar
TIPRANKS  ·  06-05
Vor Biopharma’s Phase 3 Sjögren’s Trial Puts Telitacicept on Investors’ Radar
Vor Bio grants 61,050 stock options, 12,900 RSUs to new hires under inducement plan
Reuters  ·  06-02
Vor Bio grants 61,050 stock options, 12,900 RSUs to new hires under inducement plan
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
THOMSON REUTERS  ·  06-02
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Vor Biopharma Price Target Maintained With a $31.00/Share by HC Wainwright & Co.
Dow Jones  ·  05-19
Vor Biopharma Price Target Maintained With a $31.00/Share by HC Wainwright & Co.
Vor Bio price target raised to $18 from $15 at Wedbush
TIPRANKS  ·  05-15
Vor Bio price target raised to $18 from $15 at Wedbush
Vor Biopharma Is Maintained at Neutral by Wedbush
Dow Jones  ·  05-14
Vor Biopharma Is Maintained at Neutral by Wedbush
Wedbush Adjusts Price Target on Vor Biopharma to $18 From $15, Maintains Neutral Rating
MT Newswires Live  ·  05-14
Wedbush Adjusts Price Target on Vor Biopharma to $18 From $15, Maintains Neutral Rating
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Staar Surgical (STAA), Halozyme (HALO) and Vor Biopharma (VOR)
TIPRANKS  ·  05-14
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Staar Surgical (STAA), Halozyme (HALO) and Vor Biopharma (VOR)
Vor Biopharma Q1 Adj. EPS $(0.73) Beats $(0.78) Estimate
Benzinga  ·  05-13
Vor Biopharma Q1 Adj. EPS $(0.73) Beats $(0.78) Estimate
Earnings Flash (VOR) Vor Biopharma Posts Q1 Net Loss $5.11 a Share, vs. FactSet Est of $0.78 Loss
MT Newswires Live  ·  05-13
Earnings Flash (VOR) Vor Biopharma Posts Q1 Net Loss $5.11 a Share, vs. FactSet Est of $0.78 Loss
Vor Biopharma Q1 net loss widens
Reuters  ·  05-13
Vor Biopharma Q1 net loss widens

Introduction

Company Name.
Vor Biopharma Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Vor Biopharma Inc., a clinical-stage company, engages in the development of engineered hematopoietic stem cell (eHSC) therapies for cancer patients. The company is developing lead product, tremtelectogene empogeditemcel (trem-cel), formerly VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. It also offers Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, currently under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system, currently under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system, made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, currently under preclinical studies for the treatment of AML. Vor Biopharma Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Issue price:
--